Research published on November 5 in the journal Science could lead to eye drops that restore transparency to lenses clouded by cataracts using a newly discovered chemical compound.
The American research team’s study began with 2,450 compounds and was eventually narrowed down to 32 chemicals based on lanosterol, which was shown to have cataract reversing properties, though lanosterol’s poor solubility required it to be injected directly into the lens.
One of these chemicals, referred to as “compound 29”, was settled on as the most likely candidate. Compound 29 was soluble enough to be delivered in eye drops, and was able to bind to the crystallins in the lens and break up the insoluble clumps of proteins causing clouding.
In vivo tests on mice showed that eye drops containing compound 29 restored transparency to lenses affected by cataracts, as did ex vivo tests on human lens tissue, though study lead Jason Gestwicki cautions that transparency measurements are not a direct measurement of visual acuity.
Viewpoint Therapeutics, founded by study co-author Leah Makley, is developing compound 29 for human use as a cataract treatment.
Further information: https://www.ucsf.edu/news/2015/11/176886/eye-drops-could-clear-cataracts-using-newly-identified-chemical
Alternative & Plan B Eyewear have become the new Canadian distributors for ThinOptics, a revolutionary new product that will ensure you always have your reading glasses with you! These frames weigh less than a nickel and are made from shatter-proof polycarbonate, the same material used for high-end prescription lenses. Comfortable and stable nose-pads ensure a universal fit for all face shapes. Featuring flex-grip technology with a titanium bridge, they are 10x more elastic than spring steel and guaranteed to hold up against wear and tear.
